Advanced Search

 

Study ID Status Title Patient Level Data
MT400-101 (112490) Completed A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-102 (112491) Completed A study to evaluate the effect of food on the bioavailability of a sumatriptan succinate and naproxen sodium combination tablet in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-103 (112492) Completed A study to evaluate the bioavailability of different dose combinations of sumatriptan succinate and naproxen sodium 500 mg in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MT400-104 (112493) Completed An open-label study to investigate the effect of migraine attacks on the pharmacokinetics of a single dose of Treximet™ (formerly known as Trexima™) administered both during and outside of a migraine attack Study Listed on ClinicalStudyDataRequest.com
MT400-105 (112494) Completed A study to evaluate the pharmacokinetics and tolerability of two single Treximet™ (formerly known as Trexima™) tablets (administered two hours apart) in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
MUP177 Completed A single blind study to determine the extent of subject preference for Bactrobana cream over a range of creams and ointments.
MY-060/BRL-029060/1. Completed A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.
N6571300 Completed A double blind randomised placebo controlled trial in school going children to evaluate the impact of a micronutrient fortified nutritional powder on physical performance measures
NAA104606 Completed A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia
NAA105416 Completed Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg.
NAA105737 Completed A single blind, double dummy, placebo controlled, randomized, 2 period crossover study to assess the relative bioavailability of a 120mg tablet compared to two 60 mg SB-773812 tablets in healthy volunteers
NAI10901 Completed A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Effect of Inhaled Zanamivir 10mg od for 28 Days on Anti-Haemagglutinin Antibody Production (HAI Titre) Following Co-administration with Fluvirin™ Trivalent Influenza Vaccine in Healthy Adult Subjects
NAI10902 Completed An open label, randomized evaluation of the direct measurement of zanamivir concentrations in respiratory secretions following a single dose inhalation of 10mg RELENZA™ via DISKHALER in health volunteers
NAI30008 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
NAI30009 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. Study Listed on ClinicalStudyDataRequest.com
NAI30010 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Study Listed on ClinicalStudyDataRequest.com
NAI30012 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years. Study Listed on ClinicalStudyDataRequest.com
NAI30015 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Study Listed on ClinicalStudyDataRequest.com
NAI30020 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients Study Listed on ClinicalStudyDataRequest.com
NAI30028 Completed A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children. Study Listed on ClinicalStudyDataRequest.com
NAI30031 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households Study Listed on ClinicalStudyDataRequest.com
NAI30034 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk … Study Listed on ClinicalStudyDataRequest.com
NAI40012 Completed An Open-Label, Multi-center Study of the Patient Instructional Leaflet for RELENZA DISKHALER.
NAIA1009 Completed Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness. Study Listed on ClinicalStudyDataRequest.com
NAIA3002 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.